Insight Molecular Diagnostics Reports 99% Revenue Decline in Q1 2026

Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, reported a significant decline in revenue for the first quarter of 2026, with net revenue falling to $32,000 compared to $2.1 million in the same period last year. This 99% decrease was primarily attributed to a strategic shift away from laboratory services towards the commercialization of its transplant kitted tests. The company recorded a net loss of $4.3 million, an improvement from the $6.7 million loss reported in the prior year, largely due to a favorable change in the fair value of contingent consideration liabilities.

The company's total operating expenses for the quarter were $4.4 million, down from $8.1 million in the previous year. The reduction was driven by a decrease in costs associated with laboratory services, which fell by $796,000. However, research and development expenses increased by 69% to $5.0 million as iMDx continued to invest in the development of its GraftAssure product line, which includes GraftAssureCore, GraftAssureIQ, and GraftAssureDx. Sales and marketing expenses also rose by 99% to $2.4 million, reflecting the company's efforts to ramp up its marketing activities related to its transplant diagnostics.

As of March 31, 2026, iMDx reported total assets of $40.4 million, a substantial increase from $25.8 million at the end of 2025. This growth was primarily driven by a significant increase in cash and cash equivalents, which rose to $28.2 million from $11.6 million, following successful capital raises in February 2026 that generated approximately $26 million in net proceeds. The company’s accumulated deficit stood at $405.1 million, indicating ongoing challenges in achieving profitability.

Operationally, iMDx is focused on expanding its market presence in the organ transplant sector, leveraging its partnership with Bio-Rad Laboratories for the development and commercialization of its kitted transplant products. The company has also entered into a Specimen Collection Agreement with a national reference lab provider to enhance its testing capabilities. iMDx is actively pursuing regulatory approvals for its GraftAssureDx test, with a data package submitted to the FDA in March 2026.

Looking ahead, iMDx anticipates continued operating losses and negative cash flows as it invests in research and development and marketing efforts. The company remains committed to its strategic focus on transplant diagnostics while exploring opportunities for geographic expansion and potential collaborations to enhance its product offerings.